Teva Pharmaceutical Industries Limited (TLV:TEVA)
9,953.00
-137.00 (-1.36%)
At close: Jan 1, 2026
Teva Pharmaceutical Industries Employees
As of December 31, 2024, Teva Pharmaceutical Industries had 35,686 total employees, including 33,892 full-time and 1,794 part-time employees. The number of employees decreased by 786 or -2.16% compared to the previous year.
Employees
35,686
Change (1Y)
-786
Growth (1Y)
-2.16%
Revenue / Employee
1.60M ILS
Profits / Employee
67.86K ILS
Market Cap
114.15B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35,686 | -786 | -2.16% |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% |
| Dec 31, 2022 | 35,125 | -854 | -2.37% |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% |
| Dec 31, 2020 | 38,372 | -1,667 | -4.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Danel (Adir Yeoshua) | 4,290 |
| Novolog (Pharm-Up 1966) | 936 |
| Kamada | 420 |
| InterCure | 320 |
| Bait Bakfar | 227 |
| Ilex Medical | 178 |
| SofWave Medical | 126 |
| BrainsWay | 120 |
Teva Pharmaceutical Industries News
- 5 days ago - Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story - The Motley Fool
- 7 days ago - $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today - Benzinga
- 8 days ago - Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift - Benzinga
- 8 days ago - S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive - Financial Post
- 8 days ago - S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - GlobeNewsWire
- 8 days ago - Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - The Motley Fool
- 8 days ago - Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) - Seeking Alpha
- 10 days ago - Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News - GuruFocus